Ingevity Stock Price, News & Analysis (NYSE:NGVT)

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NGVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NGVT, but not buy additional shares or sell existing shares.
View NGVT analyst ratings or view top-rated stocks.

4 analysts have issued 12 month price objectives for Ingevity's shares. Their NGVT share price targets range from $43.00 to $55.00. On average, they anticipate the company's share price to reach $50.00 in the next twelve months. This suggests a possible upside of 28.7% from the stock's current price.
View analysts price targets for NGVT or view top-rated stocks among Wall Street analysts.

Ingevity's stock was trading at $70.44 on January 1st, 2023. Since then, NGVT stock has decreased by 44.8% and is now trading at $38.85.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our NGVT earnings forecast.

Ingevity Co. (NYSE:NGVT) issued its earnings results on Wednesday, November, 1st. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.22 by $0.01. The company earned $446 million during the quarter, compared to analysts' expectations of $464.28 million. Ingevity had a net margin of 7.45% and a trailing twelve-month return on equity of 22.18%. The firm's quarterly revenue was down 7.5% compared to the same quarter last year. During the same period in the prior year, the business earned $2.09 earnings per share.

ETFs with the largest weight of Ingevity (NYSE:NGVT) stock in their portfolio include Invesco S&P SmallCap Materials ETF (PSCM), ProShares Smart Materials ETF (TINT), Putnam BioRevolution ETF (SYNB) and Thrivent Small-Mid Cap ESG ETF (TSME).Avantis U.S. Small Cap Equity ETF (AVSC).

2 employees have rated Ingevity Chief Executive Officer John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among the company's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

Ingevity's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (5.71%), LSV Asset Management (3.86%), Victory Capital Management Inc. (3.25%), Brown Advisory Inc. (2.05%), American Century Companies Inc. (1.36%) and Charles Schwab Investment Management Inc. (1.21%). Insiders that own company stock include Erik Spencer Ripple, Phillip John Platt, Richard Allen White Jr and Stuart Edward Jr Woodcock.
View institutional ownership trends.

Shares of NGVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.